PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer

Breast Cancer Research and Treatment

Volumn 135, Issue 1, 2012, Pages 301-306

  Prat, A ^a,b,c   Parker, J S ^b,c   Fan, C ^c   Perou, C M ^b,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; Gene expression; Microarrays; PAM50; Prognosis

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; TAXANE DERIVATIVE;

ARTICLE; AURKA GENE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; ERBB2 GENE; ESR1 GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC MODEL; GENETIC VARIABILITY; HUMAN; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; TUMOR GENE;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84865125800     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2143-0     Document Type: Article

References (32)

1. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423 (Pubitemid 36842560)
4. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23
5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn H-J, Members P (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747
6. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104:311-325
7. Prat A, Ellis M, Perou C (2011) Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 6:48-57
8. Chin K, DeVries S, Fridlyand J, Spellman P, Roydasqupta R, Kuo W, Lapuk A, Neve R, Quian Z, Ryder T et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10:529-541 (Pubitemid 44854748)
9. Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459(7249):1005-1009
10. Li Q, Eklund AC, Juul N, Haibe-Kains B, Workman CT, Richardson AL, Szallasi Z, Swanton C (2010) Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS ONE 5(12):e15031
11. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr H-A, Hengstler JG, Kolbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405-5413
12. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C et al (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:4111-4119
13. Minn A, Gupta G, Siegel P, Bos P, Shu W, Giri D, Viale A, Oshen A, Gerald W, Massague J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518-524 (Pubitemid 41112921)
14. Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009 (Pubitemid 35461656)
15. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt A, Gillet C, Ellis P, Ryder K, Reid J et al (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9(1):239 (Pubitemid 351804039)
16. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS et al (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207-3214 (Pubitemid 46944903)
17. Korkola J, Blaveri E, DeVries S, Moore D, Hwang ES, Chen Y-Y, Estep A, Chew K, Jensen R, Waldman F (2007) Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. BMC Cancer 7(1):61 (Pubitemid 46647961)
18. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272 (Pubitemid 43264710)
19. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679 (Pubitemid 40260888)
20. Zhang Y, Sieuwerts A, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span P, Hicks D, Crowe J et al (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116(2):303-309
21. Popovici V, Chen W, Gallas B, Hatzis C, Shi W, Samuelson F, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T (2010) Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12(1):R5
22. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi M-B, Harpole D, Lancaster JM, Berchuck A et al (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074):353 (Pubitemid 43128862)
23. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29):4660-4671 (Pubitemid 41032603)
24. EXPO Project of the International Genomics Consortium (IGC). https://expo.intgen.org/geo/. Accessed 20 May 2012
25. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM (2003) Gene expression predictors of breast cancer outcomes. Lancet 361(9369):1590-1596 (Pubitemid 36578995)
26. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ et al (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24(26):4236-4244 (Pubitemid 46630780)
27. Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J et al (2011) DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 3(12):726-741
28. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7:R953-R964
29. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68
30. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550-13555 (Pubitemid 41420886)
31. Perou C, Parker J, Prat A, Ellis M, Bernard P (2010) Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 11(8):718-719
32. Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA (2007) Challenges in projecting clustering results across gene expression profiling datasets. J Natl Cancer Inst 99(22):1715-1723 (Pubitemid 351767219)